Provided by Tiger Trade Technology Pte. Ltd.

Atai Beckley Inc

7.38
-0.0400-0.54%
Post-market: 7.30-0.0800-1.08%19:59 EDT
Volume:4.31M
Turnover:31.97M
Market Cap:2.73B
PE:-3.46
High:7.45
Open:7.41
Low:7.38
Close:7.42
52wk High:7.45
52wk Low:3.27
Shares:369.95M
Float Shares:294.14M
Volume Ratio:0.51
T/O Rate:1.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1359
EPS(LYR):-2.9137
ROE:-417.21%
ROA:-39.03%
PB:15.48
PE(LYR):-2.53

Loading ...

Earnings Flash (ATAI) AtaiBeckley Posts Q1 Net Loss $0.08 a Share, vs. FactSet Est of $0.10 Loss

MT Newswires Live
·
May 12

AtaiBeckley Q1 revenue falls, net loss widens on higher expenses

Reuters
·
May 12

Atai Beckley Q1 FY26 net loss widens to $29.8 million; revenue drops to $954,000

Reuters
·
May 12

BRIEF-AtaiBeckley Inc Q1 EPS USD -0.08

Reuters
·
May 12

Ataibeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

THOMSON REUTERS
·
May 12

Ataibeckley Inc Q1 EPS USD -0.08

THOMSON REUTERS
·
May 12

Ataibeckley Inc Q1 Operating Expenses USD 31.855 Million

THOMSON REUTERS
·
May 12

Press Release: AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Dow Jones
·
May 12

AtaiBeckley Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
May 09

Atai Beckley N.V. (ATAI) Receives a Buy from H.C. Wainwright

TIPRANKS
·
Apr 29

AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research

GlobeNewswire
·
Apr 27

FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. -- Barrons.com

Dow Jones
·
Apr 25

Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. -- Barrons.com

Dow Jones
·
Apr 24

Atai Beckley publishes 2025 annual report

Reuters
·
Apr 23

Atai Beckley CMO Craig Kevin James disposes 42,579 shares worth $212,895

Reuters
·
Apr 23

Atai Beckley announces annual shareholder meeting via webcast

Reuters
·
Apr 23

Analysts Offer Insights on Healthcare Companies: Atai Beckley N.V. (ATAI) and Greenwich LifeSciences (GLSI)

TIPRANKS
·
Apr 22

Ataibeckley Announces Additional Phase 2a Results for Emp-01 (Oral R-Mdma) Showing Large and Consistent Improvements in Social Anxiety Disorder

THOMSON REUTERS
·
Apr 22

Ataibeckley Inc: Emp‑01 Was Generally Safe and Well Tolerated, No Severe or Serious Adverse Events

THOMSON REUTERS
·
Apr 22

Ataibeckley Inc: Emp-01 Demonstrated Large, Clinically Meaningful Reduction in Patient-Reported Sad Symptoms at Day 43

THOMSON REUTERS
·
Apr 22